Amphastar Pharmaceuticals
AMPH
134 hedge funds and large institutions have $442M invested in Amphastar Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 46 increasing their positions, 36 reducing their positions, and 6 closing their positions.
433% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 6
28% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 36
24% more funds holding
Funds holding: 108 → 134 (+26)
11% more capital invested
Capital invested by funds: $397M → $442M (+$45.3M)
3.6% more ownership
Funds ownership: 44.61% → 48.21% (+3.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$12M |
| 2 |
Renaissance Technologies
New York
|
+$2.44M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
+$2.41M |
| 4 |
MCM
Matarin Capital Management
New York
|
+$2.39M |
| 5 |
MAM
Martingale Asset Management
Boston,
Massachusetts
|
+$1.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MSL
Mackay Shields LLC
New York
|
-$2.41M |
| 2 |
Goldman Sachs
New York
|
-$1.22M |
| 3 |
BlackRock
New York
|
-$1.2M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.01M |
| 5 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$682K |
AMPH Hedge Fund Activity: Q4 2018 in Review
134 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q4 2018, worth a combined $442M — up 11% from $397M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new AMPH positions and 6 closed out — a net gain of 26 holders — while 46 added to existing stakes and 36 trimmed.
The largest buyer was Invesco, adding an estimated $12M. The largest seller was Mackay Shields LLC, cutting an estimated $2.41M.
- 134 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q4 2018, up from 108 in Q3 2018.
- Funds reported $442M of Amphastar Pharmaceuticals stock for Q4 2018, up 11% quarter-over-quarter.
- 32 funds opened new Amphastar Pharmaceuticals positions in Q4 2018 and 6 closed out, a net change of +26 holders.
- The largest Amphastar Pharmaceuticals buyer in Q4 2018 was Invesco, an estimated $12M added.
- The largest Amphastar Pharmaceuticals seller in Q4 2018 was Mackay Shields LLC, an estimated $2.41M sold.
Based on aggregated 13F filings for Q4 2018.